As platforms for therapeutic agents, monoclonal antibodies (MAbs) have already been
approved, and several MAbs have demonstrated clinical effectiveness in a variety of …

In the past decade, more than 20 therapeutic antibodies have been approved for clinical use
and many others are now at the clinical and preclinical stage of development. Fragment …

Over the past decade, the clinical utility of monoclonal antibodies has been realized and
antibodies are now a mainstay for the treatment of cancer. Antibodies have the unique …

Simple Summary Monoclonal antibody (mAb) therapy has been an important addition to the
therapeutic arsenal in B-cell malignancies. MAbs can induce cytotoxicity against B-cell …

In the last two decades, monoclonal antibodies have revolutionized the therapy of cancer
patients. Although antibody therapy has continuously been improved, still a significant …

The therapeutic efficacy of some anti-tumor monoclonal antibodies (mAbs) depends on the
capacity of the mAb to recognize the tumor-associated antigen and induce cytotoxicity via a …

During last two decades, the chimerization and humanization of monoclonal antibodies
(mAbs) have led to the approval of several for the treatment of cancer, autoimmune …

A unique property of monoclonal antibodies, and a principal reason for their success as
cancer therapeutics, is their ability to engage the immune system. A growing set of data …

The targeting of surface antigens expressed on tumor cells by monoclonal antibodies
(mAbs) has revolutionized cancer therapeutics. One mechanism of action of antibody-based …

In recent years, therapy with monoclonal antibodies has become standard of care in various
clinical applications. Despite obvious clinical activity, not all patients respond and benefit …